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0.56; 95%CI [0.33-0.95]). Subgroup analysis including only OSA showed a
similar result after adjustement (p=0.017; HR: 0.40; 95%CI [0.19-0.95]). In
multivariate cox analysis including all the polygraphic variables, only CSR
and minimal oxyhemoglobin saturation predicted adverse outcomes in all CHF
patients untreated for SDB but AHI.
Conclusion: In patients with CHF, ventilatory treatment of SDB is associ-
ated with a better outcome independently of confounding factors.
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Diagnostic performance of midregional proadrenomedullin in heart
failure: comparison with brain natriuretic peptide levels and the echo-
cardiographic assessment of left ventricular filling pressures
Delphine Baudouy [Orateur], Pamela Moceri
CHU Nice, Hôpital Pasteur, Cardiologie, Nice, France
Background: Acute decompensated heart failure is a challenging diagnosis
when natriuretic peptides are misleading. Midregional-proadrenomedullin
(MR-proADM) is a new prognostic peptide in heart failure.
Objectives: This preliminary study sought to assess the diagnostic accu-
racy of MR-proADM in heart failure in comparison with B-type natriuretic
peptide (BNP) according to the echocardiographic estimation of left ventric-
ular filling pressures (LVFP). The second purpose was to establish a cut-off
value of MR-proADM between stable and decompensated heart failure.
Methods: We measured BNP and MR-proADM plasma levels in 35 con-
secutive patients. Concomitantly, we performed a doppler echocardiography,
measuring the ratio of mitral velocity to early diastolic velocity of the mitral
annulus (E/e'). 25 patients were suspected of congestive heart failure and 10
patients were suffering from stable heart failure.
Results: Ischemic and dilated cardiomyopathies were the two major causes
of heart failure in our population (43% vs 31%), with only 17% of heart
failure with preserved ejection fraction. Median MR-proADM and BNP levels
were 0,94 nmol/L and 552 pg/mL respectively. Both plasma levels were
scaling up with the NYHA classification. The correlation between the E/e’
ratio and BNP levels was better than between E/e' and MR-proADM levels
(r=0,63 vs 0,41 respectively). A mild correlation was found between BNP and
MR-proADM, probably due to their shared prognostic value. MR-proADM
could classify most of the patients with intermediate BNP levels according to
the echocardiographic estimation of LVFP.
Conclusions: This preliminary study shows that MR-proADM may be of
interest for the diagnosis of decompensated heart failure in patients with inter-
mediate BNP levels. MR-proADM levels > 0,74 nmol/L would correlate with
the elevation of LVFP as determined by the E/e’ ratio, and thus be useful
when echocardiography is not available.
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Metaboreflex attenuation as a potential cause of improvement in the
ventilatory response after cardiac resynchronization therapy
Jérémie Jaussaud [Orateur], Laurie Aimable, Pierre Bordachar, Raymond
Roudaut, Hervé Douard
CHU Bordeaux, Bordeaux, France
Background: Patients suffering from heart failure (HF) have constant
exaggerated hyperventilation (high VE/VCO2) leading to breathlessness and
reduced exercise capacity. Metaboreflex over activation has been proposed to
partly explain this high ventilatory response during exercise.
Objective: We aim to investigate the modification of the metaboreflex
activation as a determinant in the improvement of the ventilatory response
6 months after CRT.
Methods and results: 10 HF patients (mean left ventricular ejection (LVEF)
27±4%, peak VO2 14±4 ml/kg/min, NYHA class 2,6±0,5; QRS duration
>120 ms) schedulded for CRT implantation were prospectively studied. At base-
line and after 6 month follow up two maximal cardiopulmonary exercise tests with
and without regional circulatory occlusion (RCO) were performed with contin-
uous VE, respiratory ratio (RR), VCO2 and VO2 measurements. RCO was
achieved by inflation of bilateral upper thigh tourniquets 30 mmHg above peak
systolic blood pressure during 3 minutes after peak exercise as previously
described. Metaboreflex contribution to the ventilatory response was assessed as
the difference in ventilatory data at the third minute during recovery between the
two tests (RCO – no RCO=). At baseline, patients had enhanced VE/VCO2
slope (40±9) and an evident metaboreflex contribution to the high ventilatory
response (VE: 3±4 L/min; p=0.01, RR: 4.5±4/min; p=0.01). 6 months after
CRT implantation, NYHA class, LVEF, peak VO2 and VE/VCO2 were signifi-
cantly improved (1,5±0,5; p<0.001, 42±7%; p<0.001, 16±4 ml/kg/min; p=0.005;
33±9; p=0.001). Metaboreflex contribution to ventilation was reduced compared
with baseline (VE: –1±5; p=0.08, RR: –1±3; p=0.01).
Conclusion: 6 months after CRT metaboreflex contribution to ventilation
is reduced and appears as an explanation in the ventilatory response improve-
ment in HF population.
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Colette Rio [Orateur], Pierre Nazeyrollas, Angeline Martin, Raphael San-
dras, François Lesaffre, Sophie Tassan-Mangina, Benoit Hercé, Jean
Pierre Chabert, Damien Metz
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Introduction: it remains controversial whether pacemaker lead implanta-
tions could interfere with tricuspid valve function. The use of rigid and thicker
ventricular leads with implantable cardioverter-defibrillators (ICD) may
increase this risk. We realised a prospective study to analyse the tricuspid
valve function in this setting.
Method: we included patients needing a first ICD between october 2009
and may 2010 and performed echocardiographic recordings the day before
implantation, during the 3 following days and at 6 weeks. These records were
analysed offline independently by 2 cardiologists to assess and grade tricuspid
valve regurgitation (TR) using PISA and semi-quantitative method, and to
measure ventricular dimensions, function and pressures.
Results: we included 32 patients, 29 males, aged 61±14. Hypokinetic car-
diopathy accounted for 26 and 24 were implanted for primary prevention.
Ejection fraction was 35±14 %. Non significant TR was found in 23 patients
and only 2 patients has a tricuspid regurgitation greater than mild. The only
significant changes occurring immediately after defibrillator implantation con-
cerned TR, with a mean volume raising from 3.1±3.2 ml to 6.1±7.0 ml
(p<0.01) and a ROS from 0.03±0.3 to 0.06±0.07 cm² (p<0.01). Six TR
changed from not significant to minime (3) or mild (3), 3 from minime to
mild. Two patients with a baseline mild TR raised the regurgitant volume
from 11 ml to 19 ml and 30 ml. Mean regurgitant fraction increased from
5.5% to 10.5% and was higher in patients with a low ejection fraction and
mild TR at baseline. At 6 weeks, the results were similar. From a clinical
standpoint, no death occurred, and no worsening of heart failure was noticed.
Conclusion: we found a significant but minor increase in TR after defibril-
lator implantation, with no foreseeable consequences. However, our data hint
that this increase may be relevant in patients with the greater baseline regur-
gitation and the lower cardiac output
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Purpose: Cardiovascular disease patterns are changing in Africa. We
aimed to document the current heart failure (HF) patterns in Djibouti.
Methods: We prospectively included Djiboutian adults hospitalized for HF
in the French Military Hospital (Djibouti) between August 2008 and
December 2010. Clinical and prognosis data were recorded.
Results: Among 1688 adults hospitalized in the medicine department, 45
(2.7%) had symptomatic HF: 38 (84%) males, mean age 55.8 years (range 27-75).
Twenty five (56%) patients were initially hospitalized for acute pulmonary
oedema. New York Heart Association (NYHA) class was 2 (40%), 3 (44%) and
